Skip to main content Skip to section navigation Skip to footer

ClearPoint Neuro, Inc.

Investor Relations

  • Investors
  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • clearpointneuro.com
This website uses cookies to improve your experience. ACCEPT REJECT

Press Releases

News & Events

News & Events

  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Jun 16, 2021 4:05pm EDT

ClearPoint Neuro, Inc. Announces Installation of ClearPoint® 2.0 Software at Mazowiecki Szpital Bródnowski in Poland

Jun 14, 2021 9:15am EDT

ClearPoint Neuro Set to Join Russell 3000® Index

Jun 08, 2021 7:30am EDT

ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease

May 19, 2021 4:05pm EDT

ClearPoint Neuro to Present at the UBS Global Healthcare Virtual Conference

May 18, 2021 4:05pm EDT

ClearPoint Neuro, Inc. Announces First-in-Human Cases of the SmartFrame Array™ Neuro Navigation System and Software

May 11, 2021 4:05pm EDT

ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame ‘Array’

May 10, 2021 5:21pm EDT

ClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic System for the MRI Suite and Operating Room

Apr 29, 2021 4:38pm EDT

ClearPoint Neuro to Announce First Quarter 2021 Results May 11, 2021

Apr 28, 2021 4:05pm EDT

ClearPoint Neuro, Inc. Congratulates Voyager Therapeutics on FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease

Apr 23, 2021 5:00pm EDT

ClearPoint Neuro Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 30
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
ClearPoint Neuro, Inc. Youtube ClearPoint Neuro, Inc. Facebook ClearPoint Neuro, Inc. Twitter ClearPoint Neuro, Inc. LinkedIn ClearPoint Neuro, Inc. Instagram
©2023 ClearPoint Neuro, Inc. All Rights Reserved.
Privacy Policy Terms of Use California Compliance Declaration Sitemap